Global /India /Healthcare /Drug Manufacturers - Specialty & Generic /AARTIDRUGS
chevron_leftBack

Aarti Drugs Ltd.

AARTIDRUGS
NSE: AARTIDRUGS Delayed
364.60INR 1.5%
4.26 USD
As of 24 April 2025, Aarti Drugs Ltd. has a market cap of $387.0M USD, ranking #13436 globally and #871 in India. It ranks #1325 in the Healthcare sector, and #325 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
13436
Country Rank
871
Sector Rank
1325
Industry Rank
325
Key Stats
Market Cap
$387.0MUSD
33.02B INR
Enterprise Value
$451.84MUSD
38.63B INR
Revenue (TTM)
$273.09MUSD
23.3B INR
EBITDA (TTM)
$33.53MUSD
2.87B INR
Net Income (TTM)
$17.88MUSD
1.53B INR
EBITDA Margin
12%
Profit Margin
6.5%
PE Ratio
21.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Prakash Patil open_in_new
Employees
1,064
Founded
1984
Website
aartidrugs.co.in open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
1.5% 9.2% 0.4% -15% -27% -27%
Upcoming Earnings
Earnings Date
Wed, Apr 30

Markets

Exchange Ticker Price
National Stock Exchange of India
MIC: XNSE
PRIMARY
AARTIDRUGS
Aarti Drugs Ltd
ISIN: INE767A01016
Shares Out.:
91.27M1 Shares Float: 34.414M2
TV:
SA:
YF:
GF:
BA:
MS:
364.60 INR
Bombay Stock Exchange
MIC: XBOM
524348 (AARTIDRUGS)
Aarti Drugs Ltd
ISIN: INE767A01016
TV:
SA:
YF:
GF:
BA:
MS:
329.05 INR
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Aarti Drugs Ltd.

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (India)
Name
Market Cap diff.
Sun Pharmaceutical Industries Ltd.
SUNPHARMA
$49.13B
4.19T INR
13K%
Divi's Laboratories Ltd.
DIVISLAB
$18.39B
1.57T INR
5K%
Cipla Ltd.
CIPLA
$14.46B
1.23T INR
4K%
Torrent Pharmaceuticals Ltd.
TORNTPHARM
$13.23B
1.13T INR
3K%
Mankind Pharma Ltd.
MANKIND
$12.47B
1.06T INR
3K%
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
Zoetis Inc.
ZTS
$67.32B
17K%
Merck KGaA
MRK
$59.42B
52.43B EUR
15K%
Takeda Pharmaceutical Company Ltd.
4502
$46.31B
6.6T JPY
12K%
Haleon plc
HLN
$45.57B
34.34B GBP
12K%
Galderma Group AG
GALD
$23.06B
19.13B CHF
6K%